The diabetes insulin pumps market is a critical segment of the medical devices industry, providing advanced insulin delivery systems for patients with type 1 and type 2 diabetes. Insulin pumps deliver insulin to the body in a controlled manner, helping people with diabetes to manage their blood sugar levels, reduce complications, and improve quality of life. With rising prevalence of diabetes, technological advancements, and improved healthcare infrastructure, this market is experiencing robust growth.

The market was valued at USD 9.33 billion in 2023, about USD 9.95 billion in 2024, and is projected to reach roughly USD 16.7 billion by 2032, growing at a CAGR of approximately 6.69%. Growth is driven by rising prevalence of diabetes, technological advancements in insulin pumps, improved healthcare infrastructure, increasing awareness about insulin pump therapy, and growing demand for effective insulin delivery systems.

By pump type, tubed pumps held a larger market share in 2024, owing to their longer history and wider acceptance among patients. However, patch pumps segment is expected to grow at a higher CAGR during the forecast period, due to their increased convenience, ease of use, and less visibility compared to tubed pumps.

By insulin reservoir capacity, 100-200 Units pumps are the most common type on the market, suitable for most patients with type 1 diabetes. 100 Units pumps are typically used by patients who require small doses of insulin, while >200 Units pumps are designed for patients who require large doses of insulin.

By delivery rate, 10 Units/Hour segment held a significant market share in 2024, catering to individuals with relatively low insulin requirements. 10-20 Units/Hour and >20 Units/Hour segments also contribute, each targeting individuals with moderate and high insulin needs, respectively.

By control mechanism, manual bolus segment held the largest market share in 2024, due to its simplicity and cost-effectiveness. However, programmable bolus segment is projected to grow at a faster CAGR during the forecast period, owing to its ability to deliver precise insulin doses at specific times. Continuous glucose monitoring (CGM) integration segment is also expected to witness significant growth, driven by increasing adoption of CGM devices for real-time glucose monitoring.

Regionally, North America dominates the market with a significant share, driven by high healthcare expenditure, technological advancements, and large diabetic population. Europe follows closely, with well-established healthcare system and high prevalence of diabetes. APAC is projected to witness substantial growth over the forecast period, due to increasing healthcare investments, government initiatives, and rising incidence of diabetes.

Key players include Novo Nordisk, Animas Corporation, Terumo Medical Corporation, BD (Becton, Dickinson and Company), Sanofi S.A., Medtronic, Tandem Diabetes Care, Johnson & Johnson, Roche Holding, Eli Lilly and Company, Merck KGaA, Smiths Medical, Insulet Corporation, Abbott Laboratories, and Ypsomed. Strategies focus on developing innovative insulin pumps, integrating CGM and AI technologies, and forming strategic partnerships.

Read more: Global Diabetes Insulin Pumps Market Research Report

People Also Ask

Q1. What are diabetes insulin pumps used for?
Diabetes insulin pumps are used for delivering insulin to patients with type 1 and type 2 diabetes, offering precise and continuous insulin delivery, which helps in better blood glucose control and reduces complications.

Q2. Which region leads the diabetes insulin pumps market?
North America leads due to high healthcare expenditure and large diabetic population, while APAC is emerging rapidly, driven by increasing healthcare investments and rising incidence of diabetes.

Tags: diabetes insulin pumps, insulin delivery, type 1 diabetes, type 2 diabetes, continuous glucose monitoring, medical devices